Share

The pharma industry briefing

The latest news, approvals and clinical trials you need to know about this month

Data: 
News in Numbers

Data: News in Numbers

 $190m

The amount Roche has agreed to pay upfront to license technology from Arrakis Therapeutics

10%  

Cancer Research UK has announced that it will cut funding to its existing grants and institutes by up to 10% 

10%

$483m

The US Government has provided $483m of federal funding to Moderna to support the development of a Covid-19 vaccine

26

According to the WHO, there are 26 diseases for which vaccines are available

2 million 

The Japanese Government has decided to increase its stockpiles of Avigan® Tablet for up to 2 million people

Data: News in Numbers

$190m

The amount Roche has agreed to pay upfront to license technology from Arrakis Therapeutics

10%

Cancer Research UK has announced that it will cut funding to its existing grants and institutes by up to 10%

 $483m 

The US Government has provided $483m of federal funding to Moderna to support the development of a Covid-19 vaccine

26

According to the WHO, there are 26 diseases for which vaccines are available

2 million

The Japanese Government has decided to increase its stockpiles of Avigan® Tablet for up to 2 million people

How confident are you that Pharma/Biotech Companies will be able to develop an effective vaccine for COVID-19 within the next 12 months?

Source: Pharmaceutical technology

How concerned are you that the coronavirus outbreak will disrupt the drug supply chain?

Source: Pharmaceutical technology

Approvals

 Koselugo (selumetinib)

The US FDA has approved this Neurofibromatosis Type 1 treatment from AstraZeneca and Merck for the treatment of paediatric patients over the age of two who have symptomatic, inoperable plexiform neurofibromatosis.

Source: Pharmaceutical Technology

Jelmyto (mitomycin gel)

The US FDA has approved UroGen’s Jelmyto (mitomycin gel) as the first non-surgical therapy to treat low-grade upper tract urothelial cancer.

Source: UroGen

Stelara (ustekinumab)

NHS Scotland has approved Janssen’s Stelara for the treatment of adult patients with moderately to severely active ulcerative colitis.

Source: Scottish Medicine Consortium 

Sevenfact

The US FDA has approved Sevenfact for the treatment and control of bleeding episodes occurring in adults and adolescents 12 years of age and older with hemophilia A or B with inhibitors.

Source: HEMA Biologics

Share this article